The Impact of PD-1 Inhibitor Combined with Bevacizumab on Tumor Immune Cells in MSS/pMMR Advanced Colorectal Cancer Patients with Failed First-Line Treatment

Xiaoqian Chen, Liang Wang, Wenkui Li, Xiaogai Lei, Zhanhong Li, Yong-Zhi Diao, Shenglin Zhang, C. Li, Chengjun Wang, Qijing Guo, Xinfu Ma, Yushuang LuoResearch Square 2024 · DOI

Abstract

Objective: To investigate the effects of PD-1 inhibitor combined with bevacizumab on tumor immune cells in patients with MSS/pMMR advanced colorectal cancer who failed first-line treatment. Methods: 40 patients were randomized into an experimental group (n=30, sintilimab + bevacizumab) and a control group (n=10, FOLFIRI + bevacizumab). Expression levels of CD8+ T cells, tumor-associated macrophages (TAMs), and tumor-associated fibroblasts (CAFs) were evaluated. Results: While differences in biomarker expression and tumor response did not reach statistical significance (P>0.05) in this small cohort, the experimental group showed higher PFS, mPFS, ORR, and DCR. The combination therapy appeared to remodel the immune microenvironment. Conclusion: The combination of sintilimab and bevacizumab can transform "cold" tumors into a "hot" immune-supportive state, enhancing anti-tumor ability while maintaining safety.

Introduction

Colorectal cancer (CRC) treatment is largely determined by microsatellite status. Patients with high microsatellite instability (MSI-H) typically respond well to immunotherapy. However, approximately 95% of metastatic CRC patients have Microsatellite Stable (MSS) or proficient Mismatch Repair (pMMR) tumors. These are considered "cold" tumors due to their lack of infiltrating immune cells and inherent resistance to standard PD-1/PD-L1 inhibitors. This study evaluates whether combining the PD-1 inhibitor sintilimab with the anti-angiogenic agent bevacizumab can "prime" these tumors for an immune response.

Methods

This prospective study, conducted at the Affiliated Hospital of Qinghai University, included 40 patients with advanced MSS/pMMR CRC who had failed first-line therapy.

  • Experimental Group (n=30): Received Sintilimab combined with Bevacizumab.
  • Control Group (n=10): Received standard FOLFIRI chemotherapy combined with Bevacizumab.

Baseline characteristics, including age, gender, and tumor stage, were balanced across both cohorts to ensure a valid comparison of treatment effects.

Table 1: Comparison of baseline clinical characteristics between the experimental and control groups.

Researchers utilized immunohistochemistry (IHC) to analyze tumor microenvironment (TME) biomarkers—specifically CD8+ T cells, TAMs, and CAFs—before and after treatment.

Results

Immune Microenvironment Remodeling

The study observed a notable shift from an immunosuppressive to an immune-supportive TME in the experimental group. CD8+ T cell infiltration increased from 10% to 50% positive expression, while the presence of cancer-associated fibroblasts (CAFs) decreased from 86.7% to 23.3%. These changes suggest that the combination therapy helps "thaw" the cold tumor environment by reducing physical and chemical barriers to immune infiltration.

Clinical Efficacy and Safety

Although the small sample size limited statistical significance (P>0.05), the experimental group showed superior clinical trends compared to the control group:

  • Disease Control Rate (DCR): 46.7% vs. 30.0%.
  • Progression-Free Survival (PFS): Median PFS was 5 months for the experimental group compared to 4 months for the control group.
  • Safety: Adverse reaction rates (such as hypertension or proteinuria) were comparable between the two groups, suggesting the immunotherapy combination is as tolerable as standard second-line chemotherapy.

Discussion

The synergy between PD-1 inhibitors and anti-angiogenic agents is central to these findings. Bevacizumab is thought to "normalize" the chaotic tumor vasculature, reducing interstitial pressure and allowing immune cells to penetrate the tumor core. Once inside, the PD-1 inhibitor (sintilimab) prevents T-cell exhaustion, enabling a more effective anti-tumor response. This dual-pronged approach addresses the primary barriers to treating the challenging MSS/pMMR colorectal cancer population.

Conclusion

Combining sintilimab and bevacizumab offers a promising strategy for MSS/pMMR advanced colorectal cancer patients who have failed first-line treatment. By transforming the "cold" tumor microenvironment into a "hot" state, this regimen improves clinical outcomes and enhances the patient's anti-tumor immune response without compromising safety. Further large-scale studies are warranted to confirm these survival benefits.

Summary updated

Abstract

<title>Abstract</title> Objective: To investigate the effects of PD-1 inhibitor combined with bevacizumab monoclonal antibody on tumor immune cells in patients with first-line treatment failure in MSS/pMMR advanced colorectal cancer. Methods: A total of 40 patients with advanced colorectal cancer who failed first-line treatment were selected using a random number table method from Qinghai University Affiliated Hospital from October 2021 to June 2023. Ten patients in the control group were treated with FOLFIRI combined with bevacizumab. The experimental group of 30 patients was treated with sintilimab combined with bevacizumab, and the post-treatment effects of the two groups of patients were compared. The expression levels of CD8+ T cells, tumor-associated macrophages, and tumor-associated fibroblasts were evaluated comprehensively to assess the effects of sintilimab combined with bevacizumab on patients with first-line treatment failure in MSS/pMMR advanced colorectal cancer. Results: There was no statistically significant difference in the positive expression rates of CD8+ T lymphocytes, TAMs, and CAFs before and after treatment in both groups (P&gt;0.05). There was no statistically significant difference in the comparison of the therapeutic effects of two groups of tumors (P&gt;0.05), but the experimental group had higher PFS, mPFS, ORR, and DCR than the control group. There was no statistically significant difference in the occurrence rate of drug-related adverse reactions after treatment between the two groups (P&gt;0.05). Conclusion: By using the combination of sintilimab and bevacizumab in the first-line treatment of MSS/pMMR advanced colorectal cancer patients who failed first-line treatment, not only can the tumor immune microenvironment of patients be improved, but it can also transform the cold tumor immune suppression state into a hot tumor immune supportive state. While ensuring the safety of drug adverse reactions, it enhances the patients' anti-tumor ability and clinical treatment effects, further increasing the clinical application value.
BibTeX
@inproceedings{chen2024impact,
  author = {Xiaoqian Chen and Liang Wang and Wenkui Li and Xiaogai Lei and Zhanhong Li and Yong-Zhi Diao and Shenglin Zhang and C. Li and Chengjun Wang and Qijing Guo and Xinfu Ma and Yushuang Luo},
  title = {{The Impact of PD-1 Inhibitor Combined with Bevacizumab on Tumor Immune Cells in MSS/pMMR Advanced Colorectal Cancer Patients with Failed First-Line Treatment}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4162252/v1},
}
Figure